Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
|
HERON THERAPEUTICS, INC. (HRTX)
|
Add to portfolio |
|
|
|
| Price: |
$9.94
| | Metrics |
| OS: |
140.8
|
M
| |
|
|
| Market cap: |
$1.4
|
B
| |
|
|
|
Net debt:
|
$116
|
M
| |
|
|
|
EV:
|
$1.52
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 86.3 | 88.6 | 146.0 | 77.5 | 30.8 | 1.3 | 0.0 | 0.0 |
| Revenue growth | -2.6% | -39.3% | 88.4% | 151.8% | 2305.6% | | | |
| Cost of goods sold | 46.0 | 36.2 | 61.6 | 27.5 | 4.6 | 0.0 | 0.0 | 0.0 |
| Gross profit | 40.3 | 52.4 | 84.3 | 50.0 | 26.2 | 1.2 | 0.0 | 0.0 |
| Gross margin | 46.7% | 59.2% | 57.8% | 64.5% | 85.1% | 97.3% | | |
| Sales and marketing | 87.2 | 63.9 | 89.8 | 64.6 | 56.6 | 47.7 | 17.3 | 8.7 |
| Research and development | 130.8 | 174.5 | 167.4 | 140.0 | 138.6 | 103.1 | 61.2 | 54.8 |
| General and administrative | 40.2 | 42.2 | 37.9 | 29.3 | 25.6 | 21.4 | 18.4 | 11.0 |
| EBIT | -217.8 | -228.2 | -210.7 | -183.9 | -194.6 | -170.9 | -96.9 | -74.6 |
| EBIT margin | -252.3% | -257.4% | -144.3% | -237.4% | -632.4% | -13363.2% | | |
| Pre-tax income | -220.7 | -227.3 | -204.7 | -178.8 | -197.5 | -173.1 | -97.6 | -76.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -220.7 | -227.3 | -204.7 | -178.8 | -197.5 | -173.1 | -97.6 | -76.4 |
| Net margin | -255.6% | -256.4% | -140.3% | -230.8% | -641.9% | -13537.4% | | |
| |
| Diluted EPS | ($2.24) | ($2.50) | ($2.50) | ($2.44) | ($3.65) | ($4.57) | ($2.95) | ($2.87) |
| Shares outstanding (diluted) | 98.5 | 90.8 | 81.8 | 73.2 | 54.0 | 37.9 | 33.1 | 26.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|